At ASCO GI 2025, Anna Dorothea Wagner and colleagues presented the EORTC-1203 “INNOVATION” trial, investigating trastuzumab (T) ± pertuzumab (P) with perioperative chemotherapy (CT) in HER2+ gastric and esophagogastric junction cancer.
Key findings:
✅ Pathological response rates improved with CT+T (53.3%) vs. CT alone (33.3%)
✅ No significant survival benefit for CT+T or CT+T+P vs. CT alone
✅ CT+T+P showed no advantage and was potentially detrimental
Under Dr. Wagner’s leadership, this study highlights the complexity of using pathological response as a survival surrogate in perioperative gastric cancer treatment. Acknowledgment to Heike Grabsch, Markus Moehler, Yoon-Koo Kang, and the research team for their contributions.
Read more: https://lnkd.in/ekeRPgak
